Grace Therapeutics (GRCE) Non-cash Items (2019 - 2020)
Grace Therapeutics (GRCE) posted Non-cash Items of -$2.0 million for Q3 2020, up 36.19% sequentially from -$3.1 million in Q2 2020, and up 59.56% YoY from -$1.2 million in Q4 2019.
Grace Therapeutics (GRCE) Non-cash Items (2019 - 2020) Analysis & Trends
Grace Therapeutics has reported Non-cash Items for 2 years, with the latest figure at -$2.0 million in Q3 2020.
- Quarterly Non-cash Items rose 59.56% year-over-year to -$2.0 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was -$4.2 million (changed N/A YoY) and the FY2020 annual result came in at $5.8 million, down 31.12% from the prior year.
- Non-cash Items rose to -$2.0 million in Q3 2020 per GRCE's latest filing, from -$3.1 million in the prior quarter.
- Over five years, Non-cash Items peaked at $5.8 million in Q1 2020 and troughed at -$7.1 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Grace Therapeutics | 37.72 Mn | 37.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -1.99 Mn |
| Sep 30, 2020 | -1.99 Mn |
| Jun 30, 2020 | -3.11 Mn |
| Jun 30, 2020 | -3.11 Mn |
| Mar 31, 2020 | 5.78 Mn |
| Mar 31, 2020 | 5.78 Mn |
| Sep 30, 2019 | -4.91 Mn |
| Sep 30, 2019 | -4.91 Mn |
| Jun 30, 2019 | -7.12 Mn |
| Jun 30, 2019 | -7.12 Mn |